Clinical Trials Directory

Trials / Conditions / Autoimmune Pulmonary Alveolar Proteinosis

Autoimmune Pulmonary Alveolar Proteinosis

11 registered clinical trials studyying Autoimmune Pulmonary Alveolar Proteinosis — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingInhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
NCT06431776
Savara Inc.Phase 3
Active Not RecruitingStudy of Human Bone Marrow Mesenchymal Stem Cells in APAP
NCT06111846
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.Phase 2
Active Not RecruitingClinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
NCT04544293
Savara Inc.Phase 3
CompletedThe Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
NCT03531996
Children's Hospital Medical Center, Cincinnati—
TerminatedSafety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
NCT03482752
Savara Inc.Phase 3
CompletedPioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
NCT03231033
Children's Hospital Medical Center, CincinnatiPhase 1
CompletedEvaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
NCT03006146
Children's Hospital Medical Center, CincinnatiPhase 1
CompletedEfficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
NCT02702180
Savara Inc.Phase 2
UnknownInhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Prot
NCT02243228
Peking Union Medical College HospitalPhase 2
CompletedInhaled GM-CSF Therapy of Autoimmune PAP
NCT00901511
Fondazione IRCCS Policlinico San Matteo di PaviaPhase 2
AvailableMolgramostim Nebulizer Solution Expanded Access Program Protocol
NCT06546098
Savara Inc.—